JP2017171685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017171685A5 JP2017171685A5 JP2017125081A JP2017125081A JP2017171685A5 JP 2017171685 A5 JP2017171685 A5 JP 2017171685A5 JP 2017125081 A JP2017125081 A JP 2017125081A JP 2017125081 A JP2017125081 A JP 2017125081A JP 2017171685 A5 JP2017171685 A5 JP 2017171685A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- solid tumor
- composition according
- peg
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 229940123237 Taxane Drugs 0.000 claims 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 210000001072 colon Anatomy 0.000 claims 3
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 239000000328 estrogen antagonist Substances 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 150000002224 folic acids Chemical class 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940076144 interleukin-10 Drugs 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000003300 oropharynx Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims 1
- 150000003057 platinum Chemical class 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
- 229960004622 raloxifene Drugs 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 208000001608 teratocarcinoma Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84832606P | 2006-09-28 | 2006-09-28 | |
| US60/848,326 | 2006-09-28 | ||
| US91560307P | 2007-05-02 | 2007-05-02 | |
| US60/915,603 | 2007-05-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014250391A Division JP6169066B2 (ja) | 2006-09-28 | 2014-12-10 | 癌を処置するためのペグ化ｉｌ−１０の使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018217411A Division JP6718494B2 (ja) | 2006-09-28 | 2018-11-20 | 癌を処置するためのペグ化ｉｌ−１０の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017171685A JP2017171685A (ja) | 2017-09-28 |
| JP2017171685A5 true JP2017171685A5 (enExample) | 2018-01-18 |
| JP6440776B2 JP6440776B2 (ja) | 2018-12-19 |
Family
ID=39304838
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530418A Active JP5105554B2 (ja) | 2006-09-28 | 2007-09-27 | 癌を処置するためのペグ化ｉｌ−１０の使用 |
| JP2012175219A Active JP5666523B2 (ja) | 2006-09-28 | 2012-08-07 | 癌を処置するためのペグ化ｉｌ−１０の使用 |
| JP2014250391A Active JP6169066B2 (ja) | 2006-09-28 | 2014-12-10 | 癌を処置するためのペグ化ｉｌ−１０の使用 |
| JP2017125081A Active JP6440776B2 (ja) | 2006-09-28 | 2017-06-27 | 癌を処置するためのペグ化ｉｌ−１０の使用 |
| JP2018217411A Active JP6718494B2 (ja) | 2006-09-28 | 2018-11-20 | 癌を処置するためのペグ化ｉｌ−１０の使用 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530418A Active JP5105554B2 (ja) | 2006-09-28 | 2007-09-27 | 癌を処置するためのペグ化ｉｌ−１０の使用 |
| JP2012175219A Active JP5666523B2 (ja) | 2006-09-28 | 2012-08-07 | 癌を処置するためのペグ化ｉｌ−１０の使用 |
| JP2014250391A Active JP6169066B2 (ja) | 2006-09-28 | 2014-12-10 | 癌を処置するためのペグ化ｉｌ−１０の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018217411A Active JP6718494B2 (ja) | 2006-09-28 | 2018-11-20 | 癌を処置するためのペグ化ｉｌ−１０の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US20080081031A1 (enExample) |
| EP (3) | EP2066336B1 (enExample) |
| JP (5) | JP5105554B2 (enExample) |
| CN (1) | CN101631560B (enExample) |
| AU (1) | AU2007314501B2 (enExample) |
| BR (1) | BRPI0719446A2 (enExample) |
| CA (1) | CA2664304C (enExample) |
| ES (1) | ES2606034T3 (enExample) |
| MX (1) | MX2009003362A (enExample) |
| NO (1) | NO346530B1 (enExample) |
| NZ (1) | NZ597098A (enExample) |
| WO (1) | WO2008054585A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2367891T3 (es) | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
| EP2066336B1 (en) * | 2006-09-28 | 2012-09-19 | Merck Sharp & Dohme Corp. | Use of pegylated il-10 to treat cancer |
| ES2655364T3 (es) * | 2008-12-17 | 2018-02-19 | Merck Sharp & Dohme Corp. | Producción de IL-10 mono- y dipegilada y sus usos |
| JP2013523726A (ja) | 2010-04-01 | 2013-06-17 | オンコレナ エービー | 腎細胞癌の改良された治療 |
| AR086207A1 (es) * | 2011-04-27 | 2013-11-27 | Univ Northshore Healthsystem | Composiciones y metodos |
| CN104245722A (zh) * | 2012-02-29 | 2014-12-24 | Ambrx公司 | 白细胞介素-10多肽结合物和其用途 |
| RU2679889C2 (ru) * | 2013-04-18 | 2019-02-14 | Армо Байосайенсиз, Инк. | Способы применения интерлейкина-10 для лечения заболеваний и расстройств |
| US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| WO2015031316A1 (en) | 2013-08-30 | 2015-03-05 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| CN105848674A (zh) * | 2013-11-11 | 2016-08-10 | 阿尔莫生物科技股份有限公司 | 将白细胞介素-10用于治疗疾病和病症的方法 |
| US20160375101A1 (en) * | 2014-01-15 | 2016-12-29 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
| EP2896400A1 (en) * | 2014-01-17 | 2015-07-22 | Université Catholique De Louvain | Method for increasing the bioavailability of inhaled compounds |
| CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
| WO2016060996A2 (en) | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| MX2017004983A (es) | 2014-10-22 | 2017-11-13 | Armo Biosciences Inc | Metodos para usar interleucina 10 para tratar enfermedades y trastornos. |
| US9808011B2 (en) | 2014-12-15 | 2017-11-07 | Biovectra Inc. | Pentacyclic triterpene compounds and uses thereof |
| WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| JP7121496B2 (ja) | 2015-05-28 | 2022-08-18 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 癌治療で使用するためのペグ化インターロイキン－１０ |
| JP7053453B2 (ja) * | 2015-08-25 | 2022-04-12 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害を治療するためのインターロイキン１０の使用方法 |
| US20180369337A1 (en) * | 2016-01-05 | 2018-12-27 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
| EP3402512A4 (en) | 2016-01-11 | 2019-09-25 | Armo Biosciences, Inc. | INTERLEUKIN-10 IN THE PREPARATION OF ANTIGEN-SPECIFIC CD8 + T CELLS AND METHOD FOR THE USE THEREOF |
| WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
| TWI780046B (zh) | 2016-05-10 | 2022-10-11 | 國立大學法人東京醫科齒科大學 | 炎症促進因子表現抑制劑、其有效成分之篩選方法、對於該方法為有用之表現匣、診斷藥及診斷方法 |
| WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3054156A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist |
| SG11202004097RA (en) * | 2017-11-09 | 2020-06-29 | Univ Nat Corp Tokyo Medical & Dental | Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method |
| CN111315398A (zh) | 2017-11-10 | 2020-06-19 | 阿尔莫生物科技股份有限公司 | 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法 |
| US20210347842A1 (en) * | 2018-06-19 | 2021-11-11 | Eli Lilly And Company | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| US11084857B2 (en) | 2018-12-05 | 2021-08-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Nsp-interleukin-10 proteins and uses thereof |
| BR102019007044A2 (pt) | 2019-04-05 | 2021-12-28 | Universidade Federal de Uberlândia | Peptídeos sintéticos com afinidade ao receptor de interleucina-10, composição farmacêutica e uso dos mesmos como imunomuduladores no tratamento de doenças autoimunes, inflamatórias ou alérgicas |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| JP2024504923A (ja) | 2021-01-11 | 2024-02-02 | シンセカイン インコーポレイテッド | 受容体ペア形成に関する組成物および方法 |
| US20240190934A1 (en) * | 2022-11-28 | 2024-06-13 | Elixiron Immunotherapeutics (hong Kong) Limited | Engineered interleukin-10 and fusion proteins thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US5714585A (en) | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| US5032396A (en) | 1989-02-17 | 1991-07-16 | Immunex Corporation | IL-7 to stimulate platelet production |
| US6217857B1 (en) | 1989-06-28 | 2001-04-17 | Schering Corporation | Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof |
| US5231012A (en) | 1989-06-28 | 1993-07-27 | Schering Corporation | Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10) |
| US5229115A (en) | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ATE116550T1 (de) | 1991-01-16 | 1995-01-15 | Schering Corp | Behandlung von neoplastischen krankenheiten mit interleukin-10. |
| EP0567586B1 (en) | 1991-01-16 | 1995-07-12 | Schering Corporation | Use of interleukin-10 in adoptive immunotherapy of cancer |
| US5571702A (en) | 1991-03-29 | 1996-11-05 | Genentech, Inc. | Amplification method for detection of human PF4A receptors |
| US5624823A (en) | 1991-11-22 | 1997-04-29 | The General Hospital Corporation | DNA encoding procine interleukin-10 |
| HU220103B (hu) * | 1992-08-20 | 2001-10-28 | Schering-Plough Corp. | IL-10 új alkalmazása |
| US5552303A (en) | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
| WO1994022473A1 (en) | 1993-04-01 | 1994-10-13 | University Of Washington | Use of interleukin 7 to improve vaccine potency |
| US5665345A (en) | 1993-05-24 | 1997-09-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting viral replication using IL-10 |
| NZ269663A (en) | 1993-07-26 | 1997-09-22 | Schering Corp | Agonists and antagonists of il-10 |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| PL175343B1 (pl) * | 1994-01-20 | 1998-12-31 | Schering Corp | Sposób pozaustrojowego wytwarzania aktywowanych jednojądrzastych komórek krwi obwodowej, kompozycja farmaceutyczna do pozaustrojowego wytwarzania aktywowanych jednojądrzastych komórek krwi obwodowej i kompozycja farmaceutyczna do leczenia nowotworów |
| US5696234A (en) | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6410008B1 (en) | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5866134A (en) * | 1995-03-24 | 1999-02-02 | Schering Corporation | Method for enhancing the antibody response to specific antigens with Interleukin-10 |
| US5770190A (en) * | 1995-07-14 | 1998-06-23 | Schering Corporation | Method of treatment of acute leukemia with inteleukin-10 |
| JP2000513321A (ja) * | 1995-07-14 | 2000-10-10 | シェーリング コーポレイション | インターロイキン１０での急性白血病の処置 |
| WO1997003715A1 (en) | 1995-07-21 | 1997-02-06 | The General Hospital Corporation | Method and apparatus of enhancing the delivery of a pharmaceutical formulation |
| GB2304047A (en) | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
| US5759859A (en) | 1996-07-15 | 1998-06-02 | United States Of America As Represented By The Secretary Of The Army | Sensor and method for detecting trace underground energetic materials |
| US5989867A (en) | 1996-09-23 | 1999-11-23 | Knappe; Andrea | DNA encoding IL-10-like homologue; related reagents |
| US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US6362276B1 (en) | 1998-01-07 | 2002-03-26 | Debio Recherche Pharmaceutique S.A. | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
| US6326482B1 (en) | 1999-04-23 | 2001-12-04 | Genentech, Inc. | SH2 domain-containing peptides |
| AU5827000A (en) * | 1999-07-16 | 2001-02-05 | Maria Teresa Bejarano | Viral il-10 uses |
| US6989377B2 (en) | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
| US20030186386A1 (en) | 2000-02-11 | 2003-10-02 | Hansen Christian Karsten | Interleukin 10 |
| KR20020091170A (ko) * | 2000-03-31 | 2002-12-05 | 아이덱 파마슈티칼즈 코포레이션 | Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용 |
| ES2367891T3 (es) * | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| AU2002307497A1 (en) | 2001-04-23 | 2002-11-05 | The Regents Of The University Of California | Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts |
| GB0212648D0 (en) | 2002-05-31 | 2002-07-10 | Immunoclin Lab Ltd | Treatment with cytokines |
| EP1391513A1 (en) | 2002-08-08 | 2004-02-25 | Cytheris | IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
| US7611700B2 (en) | 2002-09-09 | 2009-11-03 | Hanall Pharmaceuticals, Co., Ltd. | Protease resistant modified interferon alpha polypeptides |
| AU2003280315A1 (en) | 2002-11-14 | 2004-06-03 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
| ES2312820T3 (es) | 2002-11-29 | 2009-03-01 | Maria Grazia Roncarolo | Paramicina e il-10 para el tratamiento de enfermedades autoinmunes. |
| US20040136952A1 (en) | 2002-12-26 | 2004-07-15 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| EP1613274B1 (en) | 2003-04-15 | 2010-03-03 | GlaxoSmithKline LLC | Human il-18 substitution mutants and their conjugates |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| WO2005033307A1 (ja) | 2003-09-30 | 2005-04-14 | Kyowa Hakko Kogyo Co., Ltd. | 新規のリフォールディング方法およびその方法によって得られたタンパク質 |
| DK1699822T3 (da) | 2003-12-30 | 2008-08-04 | Merck Patent Gmbh | IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf |
| EP1722823A2 (en) * | 2004-02-27 | 2006-11-22 | Antisense Pharma GmbH | Pharmaceutical composition |
| US20060046961A1 (en) | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
| DE602005020837D1 (de) | 2004-12-09 | 2010-06-02 | Merck Patent Gmbh | Il-7-varianten mit reduzierter immunogenität |
| WO2006094530A1 (en) | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| EP1901769A2 (en) * | 2005-05-02 | 2008-03-26 | Avigen, Inc. | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
| US7749490B2 (en) | 2005-05-31 | 2010-07-06 | The Regents Of The University Of Colorado | Mutant IL-10 |
| EP1746161A1 (en) | 2005-07-20 | 2007-01-24 | Cytheris | Glycosylated IL-7, preparation and uses |
| US7939056B2 (en) * | 2005-11-14 | 2011-05-10 | The Brigham And Women's Hospital, Inc. | Interleukin-10 compositions for the treatment of adenocarcinomas |
| EP2066336B1 (en) * | 2006-09-28 | 2012-09-19 | Merck Sharp & Dohme Corp. | Use of pegylated il-10 to treat cancer |
| JP2010506166A (ja) | 2006-10-05 | 2010-02-25 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | デング熱の診断及び治療 |
| US8247370B2 (en) | 2006-12-04 | 2012-08-21 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
| CA2702494A1 (en) | 2007-10-19 | 2009-04-23 | The Regents Of The University Of California | Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
| US9170262B2 (en) | 2010-06-16 | 2015-10-27 | Abbvie, Inc. | Comparison of protein samples |
| US8759617B2 (en) | 2010-09-21 | 2014-06-24 | National Institute Of Agrobiological Sciences | Method for extraction and purification of recombinant proteins from transgenic plants |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| CN107405384A (zh) | 2015-03-11 | 2017-11-28 | 尼克塔治疗公司 | Il‑7部分与聚合物的缀合物 |
-
2007
- 2007-09-27 EP EP07867161A patent/EP2066336B1/en active Active
- 2007-09-27 BR BRPI0719446-3A patent/BRPI0719446A2/pt not_active Application Discontinuation
- 2007-09-27 EP EP11195048.1A patent/EP2468293B1/en active Active
- 2007-09-27 NO NO20091661A patent/NO346530B1/no unknown
- 2007-09-27 EP EP14180696.8A patent/EP2821078B1/en active Active
- 2007-09-27 ES ES14180696.8T patent/ES2606034T3/es active Active
- 2007-09-27 MX MX2009003362A patent/MX2009003362A/es active IP Right Grant
- 2007-09-27 AU AU2007314501A patent/AU2007314501B2/en active Active
- 2007-09-27 US US11/862,626 patent/US20080081031A1/en not_active Abandoned
- 2007-09-27 JP JP2009530418A patent/JP5105554B2/ja active Active
- 2007-09-27 WO PCT/US2007/020871 patent/WO2008054585A2/en not_active Ceased
- 2007-09-27 CN CN2007800409971A patent/CN101631560B/zh active Active
- 2007-09-27 CA CA2664304A patent/CA2664304C/en active Active
- 2007-09-27 NZ NZ597098A patent/NZ597098A/xx unknown
-
2009
- 2009-05-11 US US12/463,825 patent/US20090214471A1/en not_active Abandoned
-
2010
- 2010-12-22 US US12/976,063 patent/US8865652B2/en active Active
-
2012
- 2012-08-07 JP JP2012175219A patent/JP5666523B2/ja active Active
-
2014
- 2014-09-12 US US14/485,315 patent/US9364517B2/en active Active
- 2014-12-10 JP JP2014250391A patent/JP6169066B2/ja active Active
-
2016
- 2016-05-16 US US15/155,770 patent/US9833514B2/en active Active
-
2017
- 2017-06-27 JP JP2017125081A patent/JP6440776B2/ja active Active
- 2017-11-03 US US15/803,516 patent/US10568968B2/en active Active
-
2018
- 2018-11-20 JP JP2018217411A patent/JP6718494B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017171685A5 (enExample) | ||
| Araste et al. | Peptide-based targeted therapeutics: Focus on cancer treatment | |
| Dos Santos et al. | Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents | |
| JP2011079858A5 (enExample) | ||
| JP2015514109A5 (enExample) | ||
| ES2703826T3 (es) | Inmunoterapia con IL-12 destinada al cáncer | |
| JP2015505843A5 (enExample) | ||
| RU2016132759A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| EP3211001A3 (en) | Superagonists and antagonists of interleukin-2 | |
| Wang et al. | Emergence in protein derived nanomedicine as anticancer therapeutics: More than a tour de force | |
| JP2016528162A5 (enExample) | ||
| JP2015512398A5 (enExample) | ||
| Shen et al. | HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma | |
| JP2016530233A5 (enExample) | ||
| Wang et al. | Systemic administration of attenuated Salmonella typhimurium in combination with interleukin-21 for cancer therapy | |
| Lamichhane et al. | Checkpoint inhibition: will combination with radiotherapy and nanoparticle-mediated delivery improve efficacy? | |
| WO2020018996A3 (en) | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment | |
| Engel et al. | Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins | |
| JP2009510165A5 (enExample) | ||
| JP2008523067A5 (enExample) | ||
| Huang et al. | Safety of lienal polypeptide injection combined with chemotherapy in treating patients with advanced cancer | |
| JP2017515806A5 (enExample) | ||
| ES2845724T3 (es) | Micobacteria recombinante como agente inmunoterapéutico para el tratamiento de cáncer | |
| Sobti et al. | Advanced Therapeutic Approaches in Cancer Therapy |